Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022)

被引：0

作者：

Jiang, Qian ^{[1
]}

Li, Zongru ^{[1
]}

Qin, Yazhen ^{[1
]}

Li, Weiming ^{[2
]}

Xu, Na ^{[3
]}

Liu, Bingcheng ^{[4
,5
]}

Zhang, Yanli ^{[6
,7
]}

Meng, Li ^{[8
]}

Zhu, Huanling ^{[9
]}

Du, Xin ^{[10
]}

Chen, Suning ^{[11
]}

Liang, Yang ^{[12
]}

Hu, Yu ^{[2
]}

Liu, Xiaoli ^{[3
]}

Song, Yongping ^{[6
,7
]}

Men, Lichuang ^{[13
]}

Chen, Zi ^{[13
]}

Niu, Qian ^{[13
]}

Wang, Hengbang ^{[13
]}

Lu, Ming ^{[14
]}

Yang, Dajun ^{[15
,16
]}

Zhai, Yifan ^{[13
,14
]}

Huang, Xiaojun ^{[1
,17
]}

机构：

[1] Peking Univ, Peoples Hosp, Natl Clin Res Ctr Hematol Dis, Inst Hematol, 11 South St Xizhimen, Beijing 100044, Peoples R China

[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China

[3] Southern Med Univ, Nanfang Hosp, Dept Hematol, 1838 Guangzhou N Ave, Guangzhou 510515, Guangdong, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol,Haihe Lab Cell Ecosyst, Tianjin 300020, Peoples R China

[5] Blood Dis Hosp, Chinese Acad Med Sci & Peking Union Med Coll, Tianjin 300020, Peoples R China

[6] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou 450008, Henan, Peoples R China

[7] Henan Canc Hosp, Zhengzhou 450008, Henan, Peoples R China

[8] Huazhong Univ Sci & Technol, Tongji Hosp Tongji, Dept Hematol, Med Coll, Wuhan 430022, Hubei, Peoples R China

[9] Sichuan Univ, Dept Hematol, West China Hosp, 37 Guoxue Alley, Chengdu 610000, Sichuan, Peoples R China

[10] Shenzhen Univ, Shenzhen Peoples Hosp 2, Div Hematol, Affiliated Hosp 1, 3002 Sungang W Rd, Shenzhen 518000, Guangdong, Peoples R China

[11] Soochow Univ, Inst Blood & Marrow Transplantat, Jiangsu Inst Hematol,Affiliated Hosp 1,Collaborat, Natl Clin Res Ctr Hematol Dis, 11 South St Xizhimen, Suzhou 100044, Peoples R China

[12] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol, State Key Lab Oncol South China,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong Provi, Peoples R China

[13] Guangzhou Healthquest Pharm Co Ltd, Room F314,GIBI 3 Lanyue Rd, Guangzhou 510663, Peoples R China

[14] Ascentage Pharm Grp Inc, 800 King Farm Blvd Suite 300, Rockville, MD 20850 USA

[15] Ascentage Pharm Suzhou Co Ltd, 218 Xinghu St,Bldg B7,7Th Floor,Suzhou Ind Pk, Suzhou 215000, Jiangsu, Peoples R China

[16] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong Provi, Peoples R China

[17] Beijing Key Lab Hematopoiet Stem Cell Transplantat, 11 South St Xizhimen, Beijing 100044, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2023年 / 16卷 / 01期

关键词：

D O I：

10.1186/s13045-023-01414-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 16 条

[1] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang
Zongru Li
Yazhen Qin
Weiming Li
Na Xu
Bingcheng Liu
Yanli Zhang
Li Meng
Huanling Zhu
Xin Du
Suning Chen
Yang Liang
Yu Hu
Xiaoli Liu
Yongping Song
Lichuang Men
Zi Chen
Qian Niu
Hengbang Wang
Ming Lu
Dajun Yang
Yifan Zhai
Xiaojun Huang
Journal of Hematology & Oncology, 15
[2] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Jiang, Qian
Li, Zongru
Qin, Yazhen
Li, Weiming
Xu, Na
Liu, Bingcheng
Zhang, Yanli
Meng, Li
Zhu, Huanling
Du, Xin
Chen, Suning
Liang, Yang
Hu, Yu
Liu, Xiaoli
Song, Yongping
Men, Lichuang
Chen, Zi
Niu, Qian
Wang, Hengbang
Lu, Ming
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
[3] Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang
Zongru Li
Yazhen Qin
Weiming Li
Na Xu
Bingcheng Liu
Yanli Zhang
Li Meng
Huanling Zhu
Xin Du
Suning Chen
Yang Liang
Yu Hu
Xiaoli Liu
Yongping Song
Lichuang Men
Zi Chen
Qian Niu
Hengbang Wang
Ming Lu
Dajun Yang
Yifan Zhai
Xiaojun Huang
Journal of Hematology & Oncology, 16
[4] Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
Jiang, Qian
Huang, Xiaojun
Chen, Zi
Niu, Qian
Shi, Dayu
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Song, Yongping
Zhang, Yanli
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Zeng, Shan
Men, Lichuang
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yujun
Lu, Ming
Wang, Hengbang
Ji, Jiao
Yue, Changai
Yang, Dajun
Zhai, Yifan
BLOOD, 2020, 136
[5] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
Qian, Jiang
Shi, Dayu
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Song, Yongping
Zhang, Gongli
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yujun
Chen, Zi
Niu, Qian
Men, Lichuang
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
BLOOD, 2021, 138
[6] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
Jiang, Qian
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Zhang, Yanli
Song, Yongping
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yu-Jun
Chen, Zi
Niu, Qian
Men, Lichuang
Yang, Dajun
Zhai, Yifan
Huang, Xiao-Jun
BLOOD, 2022, 140
[7] Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
Qian, Jiang
Shi, Dayu
Li, Zongru
Qin, Yazhen
Zhao, Ting
Liu, Bingcheng
Chen, Zi
Niu, Qian
Men, Lichuang
Wang, Hengbang
Yang, Dajun
Zhai, Yifan
Huan, Xiaojun
BLOOD, 2021, 138
[8] Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study
Jiang, Qian
Li, Zongru
Zhang, Gongli
Hu, Yu
Li, Weiming
Song, Yongping
Li, Junmin
Zhou, Li
Liu, Bingcheng
Liu, Xiaoli
Xu, Na
Chen, Suning
Liu, Zhenfang
Zhu, Huanling
Jin, Jie
Huang, He
Qian, Sixuan
Meng, Li
Du, Xin
Zhao, Xielan
Gao, Sujun
Liang, Yang
Hou, Ming
Wang, Wei
Chen, Zi
Niu, Qian
Men, Lichuang
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
BLOOD, 2023, 142
[9] An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
Jiang, Qian
Huang, Xiaojun
Chen, Zi
Niu, Qian
Men, Lichuang
Wang, Hengbang
Ji, Jiao
Huang, Bo
Shi, Dayu
Zhao, Ting
Hou, Yue
Yang, Dajun
Zhai, Yifan
BLOOD, 2019, 134
[10] Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Cortes, Jorge E.
Sasaki, Koji
Kim, Dong-Wook
Hughes, Timothy P.
Etienne, Gabriel
Mauro, Michael J.
Hochhaus, Andreas
Lang, Fabian
Heinrich, Michael C.
Breccia, Massimo
Deininger, Michael
Goh, Yeow Tee
Janssen, Jeroen J. W. M.
Talpaz, Moshe
de Soria, Valle Gomez Garcia
le Coutre, Philipp
Deangelo, Daniel J.
Damon, Andrea
Cacciatore, Silvia
Polydoros, Fotis
Agrawal, Nithya
Rea, Delphine
LEUKEMIA, 2024, 38 (07) : 1455 - 1468

← 1 2 →